MRONJ risk of adjuvant bisphosphonates in early stage breast cancer

被引：15

作者：

Patel, V. ^{[1
]}

Mansi, J. ^{[2
]}

Ghosh, S. ^{[2
]}

Kwok, J. ^{[1
]}

Burke, M. ^{[3
]}

Reilly, D. ^{[3
]}

Nizarali, N. ^{[3
]}

Sproat, C. ^{[1
]}

Chia, K. ^{[2
]}

机构：

[1] Guys & St Thomas NHS Fdn Trust, Dept Oral Surg, Fl 23,Tower Wing, London SE1 9RT, England

[2] Guys & St Thomas NHS Fdn Trust, Dept Oncol, Fl 23,Tower Wing, London SE1 9RT, England

[3] Guys & St Thomas NHS Fdn Trust, Sedat & Special Care, Fl 23,Tower Wing, London SE1 9RT, England

来源：

BRITISH DENTAL JOURNAL | 2018年 / 224卷 / 02期

关键词：

ZOLEDRONIC ACID; PREVENTIVE MEASURES; OSTEONECROSIS; JAW; IMPLEMENTATION; MANAGEMENT; REDUCE;

D O I：

10.1038/sj.bdj.2017.1039

中图分类号：

R78 [口腔科学];

学科分类号：

1003 ;

摘要：

Medication-related osteonecrosis of the jaw (MRONJ) has most commonly been associated with bisphosphonates. The routine uses of these drugs are now well established predominantly in metastatic cancer with bone involvement, multiple myeloma, hypercalcaemia, osteoporosis and Paget's disease. Recently, however, the use of bisphosphonates in early breast cancer has shown a reduction in breast cancer recurrence and breast cancer deaths. This new indication for their use approximates to a further 20,000 women per year in the UK being prescribed bisphosphonates. In this article, we consider the dental impact of this new use of bisphosphonates, report on the rates of MRONJ seen in early breast cancer bisphosphonate trials and discuss strategies aimed at minimising the risk of bisphosphonate-exposed patients developing MRONJ.

引用

页码：74 / 79

页数：6

共 50 条

[21] Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307)
Kizub, Darya A.
Miao, Jieling
Schubert, Mark M.
Paterson, Alexander H. G.
Clemons, Mark
Dees, Elizabeth C.
Ingle, James N.
Falkson, Carla I.
Barlow, William E.
Hortobagyi, Gabriel N.
Gralow, Julie R.
SUPPORTIVE CARE IN CANCER, 2021, 29 (05) : 2509 - 2517
[22] Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307)
Darya A. Kizub
Jieling Miao
Mark M. Schubert
Alexander H. G. Paterson
Mark Clemons
Elizabeth C. Dees
James N. Ingle
Carla I. Falkson
William E. Barlow
Gabriel N. Hortobagyi
Julie R. Gralow
Supportive Care in Cancer, 2021, 29 : 2509 - 2517
[23] SCREENING WOMEN WITH EARLY STAGE BREAST CANCER AT RISK FOR CARDIAC DYSFUNCTION PRIOR TO ADJUVANT CANCER TREATMENT
Richards, Rachel
ONCOLOGY NURSING FORUM, 2019, 46 (02)
[24] Scheduling the adjuvant endocrine therapy for early stage breast cancer
Kahruman, Sera
Ulusal, Elif
Butenko, Sergiy
Hicks, Illya V.
Diehl, Kathleen M.
ANNALS OF OPERATIONS RESEARCH, 2012, 196 (01) : 683 - 705
[25] Scheduling the adjuvant endocrine therapy for early stage breast cancer
Sera Kahruman
Elif Ulusal
Sergiy Butenko
Illya V. Hicks
Kathleen M. Diehl
Annals of Operations Research, 2012, 196 : 683 - 705
[26] The Role of Taxanes in the Adjuvant Treatment of Early Stage Breast Cancer
Martine Piccart
Breast Cancer Research and Treatment, 2003, 79 (Suppl 1) : 25 - 34
[27] The role of taxanes in the adjuvant treatment of early stage breast cancer
Piccart, M
BREAST CANCER RESEARCH AND TREATMENT, 2003, 79 : S25 - S34
[28] Overview of adjuvant systemic therapy in early stage breast cancer
Newman, Lisa A.
Singletary, S. Eva
SURGICAL CLINICS OF NORTH AMERICA, 2007, 87 (02) : 499 - +
[29] Acceptance of Adjuvant Chemotherapy in Patients with Early Stage Breast Cancer
Marcinkowski, E. F.
Kauffman, R.
Ottesen, R.
Niland, J.
Yuan, Y.
Kruper, L.
Taylor, L.
Somlo, G.
Waisman, J.
Kim, J.
Vito, C.
ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S59 - S59
[30] Optimizing adjuvant chemotherapy in early-stage breast cancer
Perez, Edith
Muss, Hyman B.
ONCOLOGY-NEW YORK, 2005, 19 (14): : 1759 - 1767

← 1 2 3 4 5 →